European Commission approves talquetamab for the treatment of relapsed and refractory myelomaAccess, Myeloma22 August 2023
FDA grants talquetamab (TALVEY™) accelerated approval for relapsed or refractory myelomaAccess, Myeloma14 August 2023
Myeloma Patients Europe report finds huge inequalities in access to myeloma clinical trials in Central and Eastern EuropeAccess, Myeloma25 June 2023
The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myelomaAccess, Myeloma30 August 2022
EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myelomaAccess, Myeloma28 July 2022
Myeloma Patients Europe (MPE) relaunches Myeloma Access Atlas platformAccess, MPE, Myeloma19 October 2021
Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in EuropeAccess, AL amyloidosis23 June 2021
